Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance
Year: 2021
Type: article
Abstract: Significance We performed an in-cell screen of imatinib binding against a library of Abl kinase mutants derived from patients with imatinib-resistant chronic myeloid leukemia. The majority of mutations readily bind imatinib, posing the question of how these mutations cause resistance in patients. We identified several kinetic mutants, one of which binds imatinib with wild-type affinity but dissociates considerably faster from the mutant kinase. Using NMR and molecular dynamics, we found that this mutation increases the conformational dynamics of the mutant protein, linking conformational dynamics of the protein to drug dissociation. The results underline the importance of drug dissociation kinetics for drug efficacy and propose a kinetic resistance mechanism that may be targetable by altering drug treatment schedules.
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1229558712, Robotic assay platform, Elucidating the Role of Binding Kinetics in the Development of Abl Kinase Drug Resistance, G2355042017, G3549828030, Understanding how patient-derived resistance mutations affect the process of imatinib binding to Abl kinase, G5039928063, G5109122429, G5520316217, Medical Scientist Training Program, G5682042926, The role of reorganization energy in achieving selective kinase inhibition, G8061269918, G8328638188, Cancer Center Support Grant, Dynamics of Ligand Binding and Protein Kinase Regulation
OpenAlex ID: W3214278476
